• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Ultragenyx Pharmaceutical Inc.

    < Previous 1 2 3 Next >
    Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx to Participate in Investor Conferences in September
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers MREO RARE
    Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Tickers RARE
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.